Verastem, Inc. VSTM

BOSTON, October 02, 2026--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC

BOSTON, September 28, 2026--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.

Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected

BOSTON, September 24, 2026--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026

BOSTON, September 08, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical u

BOSTON, September 02, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences:

The average assessed fair value for Verastem has been cut from $16.13 to $14.75, pointing to a moderate reset in price targets. Analysts link this change to a more cautious stance on competition and revenue assumptions, even as many still focus on how Verastem executes on its pipeline and upcoming catalysts. As you read on, you will see how these shifting targets fit into the broader analyst narrative and what to watch as it evolves. Analyst Price Targets don't always capture the full story...

Verastem Inc (VSTM) reports $25.1 million in Q2 net product revenues, secures non-dilutive financing, and progresses its KRAS G12D inhibitor program with promising clinical data.

BOSTON, August 06, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress.

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, July 28, 2026--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer

BOSTON, July 23, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET.

BOSTON, July 22, 2026--Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated advanced NSCLC.

Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 that could triple. On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ:VSTM). The firm reduced the target price from $15 to $14, which still offers a revised upside potential of over 211%. The price target adjustment accompanies the firm’s […]